Allergic reaction to abciximab with atypical manifestations

Abciximab (reopro, eli lilly and company, indianapolis, indiana) is an intravenous agent that had been approved for treatment of acute coronary syndrome undergoing coronary interventions. it is a chimeric monoclonal antibody fragment that binds to the glycoprotein iib/iiia receptor with a potential for the development of an immune response to variable portions within the antigen binding site following its administration. we describe a 58-year-old man who developed sudden headache, short of breath, choking and restlessness after receiving abciximab for coronary intervention. discontinuation of abciximab and administration of intravenous fluids, steroid and antihistamines led to improvement of his symptoms gradually.